Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deep vs. Moderate Neuromuscular Blockade in Robotic Prostatectomy
NCT03808077Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Jan 2019
- Primary completion
- Oct 2024
- Countries
- 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Modality
- Small Molecules
- Drugs
- rocuronium
- Conditions
- prostate cancer (PCa)
01
Overview
Phase 2, randomised trial of rocuronium in prostate cancer (PCa) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Intra-Abdominal Pressure and Numeric Pain Scale. Started Jan 2019; status: active, not recruiting.
02
Design
2 arms- Study design
- Randomized
Deep Neuromuscular Blockade
Rocuronium 1.5mg/kg/hr titrated to deep paralysis (PTC 1-2)
Moderate Neuromuscular Blockade
Rocuronium 0.3mg/kg/hr titrated to moderate paralysis (TOF 1-2)
03
Who it enrols
Adult men under 80 years old with prostate cancer scheduled for elective robotic prostatectomy, ASA physical status 1-3, without severe renal impairment, neuromuscular disease, chronic pain, or recent abdominal surgery.
04
Endpoints
Primary
Intra-Abdominal Pressure
Numeric Pain Scale
Beyond the preview
Go deeper on NCT03808077.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808077.